UPDATE 1-Array says AstraZeneca not taking AZD6244 to Phase III

(Adds details, background, share movement)

Dec 19 (Reuters) - Array BioPharma Inc (ARRY.O) said AstraZeneca Plc (AZN.L), the licensee of its anti-cancer drug candidate, does not plan to take it into a late phase trial in patients with advanced melanoma.

The company said the decision was after a randomized Phase II study comparing anti-cancer drug AZD6244 monotherapy with an alkylating agent.

AstraZeneca is exploring other options to further develop the compound, the drug discovery company said in a statement.

AZD6244 is a selective MEK (MAP-erk kinase) inhibitor that was in-licensed by AstraZeneca from Array in December 2003 together with two second-generation compounds.

Array said AstraZeneca completed analysis on two smaller studies in third line advanced colorectal cancer and second line advanced non-small cell lung cancer, and neither of these studies reached their primary endpoint.

However, there was evidence of anti-tumor activity in the second line advanced non-small cell lung cancer study, it added.

Shares of Array BioPharma, which have fallen about 16 percent so far this year, lost about 18 percent of their market value to $9.05 in late electronic trade after closing at $11.02 Wednesday on the Nasdaq.

(Reporting by Supantha Mukherjee in Bangalore; Editing by Jarshad Kakkrakandy)

((supantha.mukherjee@reuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters messaging: supantha.mukherjee.reuters.com@reuters.net;)) Keywords: ARRAYBIOPHARMA/TRIAL

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nBNG155613